SUNPHARMA's weekly return of 1.34% was modest, but its volatility of 20.25% was relatively high. The stock underperformed peers DRREDDY and HINDUNILVR, but outperformed DIVISLAB in terms of return. The Sharpe Ratio of 0.27 indicates that the stock's return was not adequately compensated for its risk. Overall, SUNPHARMA was a relatively risky investment this week.

[Volatility: 20.25%]